Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.85 USD
Change Today +0.07 / 0.59%
Volume 596.3K
SRNE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

sorrento therapeutics inc (SRNE) Snapshot

Open
$11.71
Previous Close
$11.78
Day High
$12.00
Day Low
$11.00
52 Week High
03/20/15 - $14.30
52 Week Low
10/14/14 - $3.10
Market Cap
429.0M
Average Volume 10 Days
433.9K
EPS TTM
$-1.32
Shares Outstanding
36.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SORRENTO THERAPEUTICS INC (SRNE)

Related News

No related news articles were found.

sorrento therapeutics inc (SRNE) Related Businessweek News

No Related Businessweek News Found

sorrento therapeutics inc (SRNE) Details

Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company primary therapeutic focus is oncology, including the treatment of chronic cancer pain, as well as developing therapeutic products for other indications, such as immunology and infectious diseases. Its lead product, Cynviloq, is polymeric, albumin-free nanoparticle paclitaxel formulation, approved and marketed in South Korea for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I, Phase II, and Phase III clinical trials, and post-marketing surveillance studies in MBC, NSCLC, ovarian, pancreatic, and bladder cancer. The company is also developing resiniferatoxin, a non-opiate, ultra potent, and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company’s preclinical human therapeutic monoclonal antibodies include human anti- PD-L1 and anti-PD-1 checkpoint inhibitors; antibody drug conjugates; and bispecific antibodies, as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast for adoptive cellular immunotherapies. It has a collaboration agreement with Conkwest Incorporated to generate and develop products for adoptive immunocellular therapy utilizing Neukoplast cells and chimeric antigen receptors; and NantWorks, Inc. to develop anti-cancer immunotherapies. Sorrento Therapeutics, Inc. was founded in 2006 and is headquartered in San Diego, California.

66 Employees
Last Reported Date: 03/16/15
Founded in 2006

sorrento therapeutics inc (SRNE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $291.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $296.0K
Compensation as of Fiscal Year 2013.

sorrento therapeutics inc (SRNE) Key Developments

NantWorks, Inc. and Sorrento Therapeutics, Inc Collaborate to Develop New Anti-Cancer Immunotherapies

NantWorks, Inc. and Sorrento Therapeutics, Inc. have entered into a binding agreement to initiate a global collaboration to discover and develop novel anticancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach. Under the terms of the agreement, Sorrento will exclusively license to NantCell, LLC, a NantWorks company, certain antibodies and CAR-TNK products in exchange for $10 million in cash and $100 million in NantCell's equity. In addition to the equity and cash payments, Sorrento will also have a share of all future profits resulting from the collaboration.

NantWorks Signs Contract with Sorrento Therapeutics

NantWorks has signed a binding agreement with Sorrento Therapeutics. The contract has been signed for the discovery and development of new anti-cancer immunotherapies. The new products will be developed from Sorrento's G-MAB library compared with neoepitopes of tumour-specific antigens discovered using NantWorks' pan-omics based, precision medicine approach. Under the contract, Sorrento will license to NantCell, a NantWorks company, certain antibodies and CAR-TNK products and the checkpoint inhibitors PD-1 and PD-L1 in exchange for USD 10 million in cash and USD 100 million in NantCell's equity.

Sorrento Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 02:50 PM

Sorrento Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 02:50 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Henry H. Ji, Co-Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRNE:US $11.85 USD +0.07

SRNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SRNE.
View Industry Companies
 

Industry Analysis

SRNE

Industry Average

Valuation SRNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 91.4x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 89.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORRENTO THERAPEUTICS INC, please visit www.sorrentotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.